Table 4.
Patient characteristics of the ICB cohort
| Characteristics | Number N | (%) |
|---|---|---|
| All patients | 129 | 100 |
| Age in years, (range) | 67.11, (28−92) | |
| Gender | ||
| Female | 50 | 38.8 |
| Male | 79 | 61.2 |
| Site of melanoma metastases | ||
| Cutaneous metastases | 62 | 48.1 |
| Lymph node metastases | 37 | 28.7 |
| Lung metastases | 13 | 10.1 |
| Brain metastases | 11 | 8.5 |
| Abdominal metastases | 6 | 4.7 |
| BRAF mutation status | ||
| BRAF wild type | 84 | 65.1 |
| BRAF mutated | 42 | 32.6 |
| Unknown | 3 | 2.3 |
| Response to anti-PD-1 blockade | ||
| Progressive disease (PD) | 58 | 45.0 |
| Partial response (PR) | 39 | 30.2 |
| Stable disease (SD) | 8 | 6.2 |
| Complete response (CR) | 22 | 17.0 |
| Unknown | 2 | 1.6 |
| Therapeutic regimen | ||
| Anti-PD-1 monotherapy | 68 | 52.7 |
| Ipilimumab, anti-PD-1 monotherapy | 12 | 9.3 |
| Ipilimumab + nivolumab | 17 | 13.2 |
| Ipilimumab, ipilimumab + nivolumab | 2 | 1.5 |
| Anti-PD-1 monotherapy, ipilimumab + nivolumab | 30 | 23.3 |
| Medical center | ||
| University Hospital Bonn—dermatology | 104 | 80.6 |
| University Hospital Bonn—oncology | 5 | 3.9 |
| University Hospital Bonn—neurosurgery/-oncology | 4 | 3.1 |
| Kantonsspital St. Gallen, Spital Grabs, Spital Wil, Spital Flawil | 16 | 12.4 |
Data include age, gender, site of the melanoma metastases, BRAF mutation status, response to anti-PD-1 blockade, therapeutic regimen, and the treating medical center of N = 129 stage IV melanoma patients receiving immune checkpoint blockade